{"id":"cti-1601","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CTI-1601 uses a viral vector to deliver a healthy copy of the SOD1 gene to motor neurons, replacing the mutated gene that causes ALS. This approach has shown promise in preclinical studies, but its efficacy in humans remains to be determined.","oneSentence":"CTI-1601 is a gene therapy that aims to restore motor neuron function in patients with amyotrophic lateral sclerosis (ALS).","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:09:18.542Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Amyotrophic lateral sclerosis (ALS)"}]},"trialDetails":[{"nctId":"NCT06447025","phase":"PHASE2","title":"An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia","status":"RECRUITING","sponsor":"Larimar Therapeutics, Inc.","startDate":"2024-01-25","conditions":"Friedreich Ataxia","enrollment":85},{"nctId":"NCT06681766","phase":"PHASE1","title":"A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia","status":"TERMINATED","sponsor":"Larimar Therapeutics, Inc.","startDate":"2024-12-06","conditions":"Friedreich Ataxia","enrollment":18},{"nctId":"NCT05579691","phase":"PHASE2","title":"A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Larimar Therapeutics, Inc.","startDate":"2022-09-21","conditions":"Friedreich Ataxia","enrollment":28},{"nctId":"NCT04519567","phase":"PHASE1","title":"Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Larimar Therapeutics, Inc.","startDate":"2020-07-31","conditions":"Friedreich Ataxia","enrollment":27},{"nctId":"NCT04176991","phase":"PHASE1","title":"Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia","status":"COMPLETED","sponsor":"Larimar Therapeutics, Inc.","startDate":"2019-12-11","conditions":"Friedreich Ataxia","enrollment":28}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Nomlabofusp"],"phase":"phase_2","status":"active","brandName":"CTI-1601","genericName":"CTI-1601","companyName":"Larimar Therapeutics, Inc.","companyId":"larimar-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"CTI-1601 is a gene therapy that aims to restore motor neuron function in patients with amyotrophic lateral sclerosis (ALS). Used for Amyotrophic lateral sclerosis (ALS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}